Nuijten et al Cost-effectiveness results
| Cost | No discounting | Discounting (4% for cost and 1.5% for outcomes) | |||
|---|---|---|---|---|---|
| Outcomes | ICER | Outcomes | ICER | ||
| Preterm/BPD population | |||||
| Direct medical costs (including long-term sequelae: payers’ perspective) | |||||
| QALYs | ?5,369 | 0.42 | ?12,728 | 0.27 | ?20,236 |
| Total costs (including indirect costs: societal perspective) | |||||
| QALYs | ?3,007 | 0.42 | ?7,130 | 0.27 | ?11,336 |
| CHD population | |||||
| Direct medical costs (including long-term sequelae: payers’ perspective) | |||||
| QALYs | ?5,926 | 1.39 | ?4,256 | 0.84 | ?7,067 |
| Total costs (including indirect costs: societal perspective) | |||||
| QALYs | ?−2,670 | 1.39 | Dominant | 0.84 | Dominant |
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year